H.C. Wainwright lowered the firm’s price target on Oncternal Therapeutics to $19 from $28 and keeps a Buy rating on the shares post the Q1 report. The analyst cites the company’s additional equity financings in the future for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Therapeutics reports Q1 EPS ($2.83), consensus ($2.88)
- Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
- Oncternal Therapeutics reports inducement award under Nasdaq listing rule
- Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- ONCT Earnings this Week: How Will it Perform?